| 2024-04-24 | -0.24 % |
|
| 2024-04-23 | +2.15 % |
|
| 2024-04-18 | +2.17 % |
|
| 2024-04-17 | -5.97 % |
|
| 2024-04-12 | -1.93 % |
- The article discusses potential investment opportunities in the healthcare sector, highlighting CSL, ResMed, and Telix as attractive ASX-listed healthcare stocks. ResMed stock, which went down by -1.93% last night, was considered a great option for healthcare exposure due to its leadership in sleep disorder treatment solutions and the large addressable market of undiagnosed sleep apnoea sufferers, presenting a significant growth opportunity.
- The article discusses ResMed Inc. (RMD) stock, which reported a -1.93% drop in its value. The decrease in stock price may have been influenced by various factors, such as quarterly earnings estimates being slightly below expectations, despite an overall positive outlook on the company's performance by research analysts. Other factors that can influence stock prices include market conditions, investor sentiment, and company news or financial performance.
- The article discusses a forecast on Starbucks Corporation's earnings estimates by Zacks Research team, which led to a decrease in their Q2 2024 EPS estimates for the company. The stock of ResMed Inc. (RMD) went down by -1.93% due to Starbucks-related news impacting the market sentiment.
|
| 2024-04-11 | -2.21 % |
- Summary: The article compares medical companies Artivion and ResMed based on analyst recommendations, institutional ownership, dividends, profitability, valuation, risk, and earnings, noting that ResMed stock was down -2.21% last night due to factors such as lower institutional ownership, fewer insider shares, and a less affordable price-to-earnings ratio compared to Artivion.
Reason for ResMed stock decline: ResMed's stock likely went down due to lower institutional ownership, fewer insider shares, and a higher price-to-earnings ratio compared to Artivion, leading analysts to believe Artivion is more favorable in terms of growth potential.
- ResMed (RMD) stock experienced a 2.21% decrease in value last night. This decline may be attributed to concerns about the potential impact of weight loss drugs on ResMed, despite the company reporting revenue growth of 12% in the second quarter of 2024, which led to investor optimism due to the company's strong operating cash flow.
|
| 2024-04-09 | +3.47 % |
- The article discusses ResMed Inc (ASX: RMD) stock, which was up 3.47% last night due to brokers recommending it as a high-quality investment option with potential upside, primarily driven by its innovative medical devices and cloud-based solutions for sleep-disordered breathing and chronic diseases. The stock is considered undervalued despite concerns related to weight loss wonder drugs and is expected to see growth as it taps into its large addressable global market with new product launches aiding its dominant market position and continued sequential growth in device sales. Analysts from Bell Potter and Morgans have buy and add ratings on the stock, showing confidence in its ability to perform well in the market.
- Summary: ResMed Inc. (RMD) stock was up 3.47% last night, with Asset Management One Co. Ltd. increasing its position in the company, along with other institutional investors. The stock rose due to positive investor sentiment following increased institutional ownership, strong quarterly earnings results, and positive analyst ratings.
Reason for stock increase: The stock of ResMed (RMD) went up due to increased institutional investment, positive quarterly earnings results, the announcement of a dividend, insider buying/selling activities, and favorable analyst ratings.
|
| 2024-04-05 | +2.03 % |
|
| 2024-04-04 | -0.56 % |
|
| 2024-04-02 | -2.62 % |
|
| 2024-04-01 | -4.4 % |
|
| 2024-03-25 | +0.68 % |
|
| 2024-03-20 | -0.33 % |
|
| 2024-03-15 | -0.89 % |
|
| 2024-03-12 | +2.12 % |
|
| 2024-03-08 | -2.16 % |
|
| 2024-03-06 | +3.74 % |
|
| 2024-03-05 | -1.71 % |
|
| 2024-03-01 | +0.51 % |
|
| 2024-02-29 | -0.14 % |
- The article discusses the performance of Australian stocks, with the S&P/ASX 200 reaching a new all-time high and various companies experiencing gains and losses, including Resmed Inc DRC (ASX:RMD) stock which fell 4.08% at the close. Resmed (RMD) stock likely went down due to factors affecting the company specifically, such as poor earnings reports, changes in market sentiment, or internal company developments.
- The article discusses various healthcare industry updates, including a ransomware attack against Change Healthcare, UnitedHealth Group's antitrust investigation, Redi Health's funding, and other industry movements. ResMed (RMD) stock went down, possibly impacted by the widespread ransomware attack affecting the healthcare sector.
|
| 2024-02-28 | -3.88 % |
|
| 2024-02-23 | +0.51 % |
|
| 2024-02-20 | +0.11 % |
- The article discusses how ResMed Inc. (RMD) stock was 0.11% up, attributing this increase to Invesco Ltd. reducing its position in shares of ResMed in the third quarter, along with positive earnings results and dividend payout.
- The article discusses Fmr LLC reducing its stake in shares of ResMed Inc. (RMD) by 37.5% but other institutional investors like Norges Bank, abrdn plc, Renaissance Technologies LLC, Capital Research Global Investors, and Barclays PLC have recently acquired significant stakes in the company, potentially leading to increased demand for the stock. With positive earnings results and analyst ratings, the stock of ResMed (RMD) went up by 0.11% recently.
- The article discusses how ResMed Inc. (RMD) stock increased by 0.11% and provides information about institutional investors modifying their holdings, various brokerages issuing reports on RMD with upgraded price targets, and the quarterly earnings data showing positive results, with the company beating the consensus estimate. ResMed stock goes up due to positive investor sentiment, institutional interest, favorable earnings results, and analysts' optimistic ratings and price targets.
|
| 2024-02-15 | +1.14 % |
|
| 2024-02-12 | -1.14 % |
|
| 2024-02-07 | -2.17 % |
|
| 2024-02-02 | -0.93 % |
|
| 2024-02-01 | +1.82 % |
|
| 2024-01-29 | +0.57 % |
|
| 2024-01-26 | +2.04 % |
|
| 2024-01-25 | +8.48 % |
|
| 2024-01-24 | -1.82 % |
- ResMed (RMD) stock went down by 1.82% last night after the company announced its results for the quarter ended December 31, 2023, which included strong growth in its device, masks and accessories, and residential care software businesses, as well as cost discipline.
- ResMed Inc. (RMD) announced its results for the second quarter of fiscal year 2024, which showed strong double-digit growth across its device, masks and accessories, and residential care software businesses. Despite these positive results, the stock went down by 1.82% last night, and the reason for this decline is not mentioned in the article.
- The article discusses how Australian investment firm, Australian Foundation Investment Company (AFIC), is finding potential value in beaten-down lithium shares due to the sector's downturn, similar to the hasty selling in healthcare stocks caused by weight-loss drug Ozempic. AFIC increased its stakes in healthcare companies CSL and ResMed after a mid-year sell off triggered by concerns over the impact of weight-loss drugs, and shares in both companies have since rebounded. AFIC is now starting to look at the lithium sector and has bought a small position in diversified miner Mineral Resources, which produces lithium. The decline in ResMed stock is not specifically mentioned in the article, so the reason for its decline is unclear.
|
| 2024-01-22 | +2.48 % |
|
| 2024-01-17 | +0.29 % |
|
| 2024-01-09 | +2.93 % |
|
| 2024-01-08 | +3.57 % |
|
| 2024-01-03 | -3.49 % |
|
| 2024-01-02 | -0.14 % |
|
| 2023-12-27 | -0.24 % |
|
| 2023-12-20 | +0.22 % |
|
| 2023-12-18 | +0.51 % |
|
| 2023-12-13 | +2.61 % |
|
| 2023-12-12 | +2.56 % |
|
| 2023-12-11 | +0.41 % |
- ResMed's stock (RMD) went up by 0.41% after the United States Patent Trial and Appeals Board (PTAB) invalidated the claims made by New York University (NYU) against ResMed based on seven NYU patents. The ruling is a result of ResMed's petitions asserting that the claims were invalid, and the victory signifies ResMed's commitment to defending their innovations and providing patients with quality therapy solutions.
- ResMed (RMD) stock went up by 0.41% last night, and the reason behind the increase is the company's position in the growing market for sleep technologies, particularly in sleep apnea treatment and respiratory care. ResMed specializes in designing and selling medical devices, masks, diagnostic products, and software solutions for professionals and caregivers in the healthcare industry. The company operates in a colossal market, with millions of people worldwide suffering from sleep apnea and related conditions. Additionally, ResMed has diversified its activities to target respiratory pathologies and neuromuscular diseases, while also capitalizing on the demand for digital technologies in the out-of-hospital and homecare environment. Despite facing some reputational risks due to industry controversies, ResMed has impressive financial figures, with rapidly increasing revenues, high profitability, and excellent control over its cost structure. Although the stock has experienced a decline since its 2021 highs, the company is expected to maintain its growth rate and improve its margins in the future.
|
| 2023-12-07 | -0.31 % |
|
| 2023-11-29 | +2.04 % |
|
| 2023-11-24 | +0.83 % |
|
| 2023-11-20 | +1.52 % |
|
| 2023-11-16 | -2.14 % |
|
| 2023-11-13 | -0.47 % |
|
| 2023-11-09 | -3.6 % |
|
| 2023-11-08 | -0.98 % |
|
| 2023-11-06 | +0.7 % |
|
| 2023-10-27 | -2.94 % |
|
| 2023-10-26 | -1.26 % |
|
